Skip to main content
Industry News
FDA accepts NDA for Intercept's obeticholic acid

The FDA accepted the New Drug Application filed by Intercept Pharmaceuticals for obeticholic acid, which is indicated as a treatment for fibrosis as a result of non-alcoholic steatohepatitis. The filing was granted Priority Review status, and a PDUFA action date was set for March 26.

Full Story: